Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Complete title: Phase 1b, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with LCL161, everolimus (RAD001) or panobinostat (LBH589)

Research Study Number 20162431
 
Principal Investigator Jennifer Specht, MD
 
Phase I

Research Study Description

The purpose of this study is to combine the PDR001 checkpoint inhibitor with several agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20162431
 
Contact Seattle Cancer Care Alliance Intake Office
 
Telephone 800-804-8824 / 206-606-1024
 

Keywords: Breast Cancer; Colon Cancer; Lung Cancer; Rectal Cancer; Lung Carcinoma, Non-Small-Cell (NSCLC); Carcinoma, Bronchogenic; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Colorectal Neoplasms; Carcinoma; Solid Organ Transplant (SOT); Triple Negative Breast Neoplasms; Neoplasms, Respiratory Tract; Neoplasms, Thoracic; Gastrointestinal Diseases; Digestive System Diseases

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials